Management of classic congenital adrenal hyperplasia (CAH) can be a lifelong balancing act, but the most feared life-threatening complication is an acute adrenal insufficiency, also known as an ...

Neurocrine Biosciences’ newest educational campaign wants frustrated congenital adrenal hyperplasia patients to ask, “What the C@H?!” Neurocrine unveiled the campaign this week, not long after ...

Please provide your email address to receive an email when new articles are posted on . Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal ...

Phyllis Speiser is emeritus professor of pediatrics at Zucker School of Medicine at Hofstra-Northwell and associate investigator at The Feinstein Institute for Medical Research of Northwell Health.

Congenital adrenal hyperplasia (CAH) is a group of inherited conditions in which the adrenal glands cannot make certain hormones, most commonly due to a deficiency of the enzyme 21-hydroxylase. This ...

Please provide your email address to receive an email when new articles are posted on . Crinecerfont allowed lower glucocorticoid doses for children with congenital adrenal hyperplasia at 28 weeks.

Credit: Shutterstock. BBP-631 is an adeno-associated virus 5 (AAV5) gene therapy designed to deliver a functional copy of the 21-hydroxylase gene to restore the body’s ability to produce cortisol and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare ...